These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 34743366)

  • 1. Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Salman A; Apti Sengun Ö; Aktas M; Taşkapan O
    Dermatol Ther; 2022 Jan; 35(1):e15192. PubMed ID: 34743366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry.
    Kojanova M; Tanczosova M; Strosova D; Cetkovska P; Fialova J; Dolezal T; Machovcova A; Gkalpakiotis S;
    J Dermatolog Treat; 2022 Aug; 33(5):2578-2586. PubMed ID: 35170381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic.
    Tánczosová M; Kojanová M; Arenbergerová M; Arenberger P; Doležal T; Štrosová D; Fialová J; Gkalpakiotis S
    Cent Eur J Public Health; 2022 Mar; 30(1):46-50. PubMed ID: 35421298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
    J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.
    Stingeni L; Hansel K; Antonelli E; Bello GD; Patruno C; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G
    Dermatol Ther; 2021 Sep; 34(5):e15035. PubMed ID: 34152670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
    Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
    J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab for atopic dermatitis: evidence to date.
    Rodrigues MA; Nogueira M; Torres T
    G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.
    Napolitano M; Di Guida A; Fabbrocini G; Patruno C
    Dermatol Ther; 2021 Sep; 34(5):e15059. PubMed ID: 34241938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
    Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.
    Ungar B; Glickman JW; Golant AK; Dubin C; Marushchak O; Gontzes A; Mikhaylov D; Singer GK; Baum D; Wei N; Sanin A; Gruenstein D; Lebwohl MG; Pavel AB; Guttman-Yassky E
    J Allergy Clin Immunol Pract; 2022 Jan; 10(1):134-142. PubMed ID: 34737108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study.
    Hosseini-Ashrafi M; Clayton TH; Herring M; Herety N; Arkwright PD
    Clin Exp Dermatol; 2024 May; 49(6):578-583. PubMed ID: 38189448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
    Francuzik W; Alexiou A; Worm M
    Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.